Physician profile
Brian Copeland
NPI 1659573525
$6,664.11
in general payments reported to CMS, 2019-2025
38 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $272 · 2021: $699 · 2022: $894 · 2023: $1,414 · 2024: $285 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Travel and Lodging: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.39 |
| Travel and Lodging | $1,458.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,743.06 | 2024-2025 | Gi Genius |
| Abbvie INC. | $873.90 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $664.33 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.71 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $332.95 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $248.83 | 2021-2024 | Zeposia |
| Emd Serono, INC. | $238.97 | 2021 | |
| Braintree Laboratories, INC. | $212.55 | 2019-2025 | Sutab, Suflave |
| Pfizer INC. | $185.39 | 2019-2024 | |
| Boston Scientific Corporation | $141.31 | 2019-2025 | General - Biliary Devices |
| Qol Medical, LLC | $139.77 | 2019-2025 | Sucraid |
| Gilead Sciences, INC. | $127.79 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $126.56 | 2019-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $102.58 | 2019-2022 | |
| Allergan, INC. | $97.90 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $96.82 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $85.49 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.55 | 2023-2024 | Dupixent |
| Genzyme Corporation | $58.47 | 2023 | |
| Nestle Healthcare Nutrition INC. | $47.61 | 2021 | |
| Echosens North America, INC. | $43.46 | 2019 | |
| Axsome Therapeutics, INC. | $34.98 | 2023 | Sunosi |
| Dova Pharmaceuticals | $33.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $33.62 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $31.03 | 2019 | |
| Merck Sharp & Dohme LLC | $29.61 | 2019-2020 | |
| Alfasigma USA, INC. | $28.69 | 2020 | |
| Shionogi INC | $25.65 | 2019 | |
| Digestive Care, INC. | $24.01 | 2023 | Pertzye |
| Daiichi Sankyo INC. | $21.71 | 2023 | Injectafer |
| Evoke Pharma, INC. | $19.51 | 2022 | |
| Ge Healthcare | $16.82 | 2025 | |
| Lilly USA, LLC | $16.43 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $16.20 | 2025 | Voquezna |
| Redhill Biopharma INC. | $15.56 | 2022 | |
| Ambu INC. | $14.86 | 2021 | |
| Olympus America INC. | $11.56 | 2019 | |
| Concordia Pharmaceuticals INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.